Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises SBB on its offer for Entra
Mandate

Vinge advises SBB on its offer for Entra

November 30, 2020 Capital Markets and Public M&A Banking and Finance Corporate Tax

Vinge advises Samhällsbyggnadsbolaget i Norden AB (publ) (”SBB”) in connection with its public offer to the shareholders of Entra ASA.

The total offer consideration consists of a combination of cash and SBB shares, corresponding to a value of approximately NOK 30 billion. SBB is a leading Nordic social infrastructure property company with a property portfolio with a market value of SEK 81.2 billion as of 30 September 2020. SBB’s Class B and Class D common shares are listed on Nasdaq Stockholm, Large Cap. SBB’s preference shares are listed on Nasdaq First North Premier Growth Market.

Vinge’s team consists of Jesper Schönbeck, Rikard Lindahl, Malte St Cyr Ohm, Boris Kotur, Martin Boström, Emil Lindwall, Olof Löfvenberg, Lorin Arabi, Mikaela Falkner, Eléonore Friberg and Clara Sohlberg (Capital Markets and Public M&A), Albert Wållgren and Axel Jansson (Banking and Finance) as well as Victor Ericsson (Corporate tax).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025